Inflammatory bowel diseases (Crohn's disease and ulcerative colitis): cost of treatment in Serbia and the implications

Marina Kostić, Ljiljan Djakovic, Raša Šujić, Brian Godman, Slobodan M Janković

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

BACKGROUND: Although the costs of treating inflammatory bowel disease (IBD) in developed countries are well established, they remain largely unknown in countries with recent histories of socio-economic transition including Serbia.

OBJECTIVE: To estimate the costs of treatment including the resources used by patients with IBD in Serbia from a societal perspective. This includes both Crohn's disease and ulcerative colitis.

METHODS: This cost-of-illness study was conducted to identify direct, indirect and out-of-pocket costs of treating patients with IBD in Serbia. Patients with IBD (n = 112) completed a semi-structured questionnaire with data concerning their utilisation of heath-care resources and illness-related expenditures. All costs were calculated in Republic of Serbia dinars (RSD) at a 1-year level (2014) and subsequently converted to Euros. Median values and ranges were reported to avoid potential distortions associated with mean costs.

RESULTS: Median total direct costs and total indirect costs per patient per year in patients with Crohn's disease were 192,614.32RSD (€1602.97) and 28,014.00RSD (€233.13) and 142,267.15RSD (€1183.97) and 21,436.00RSD (€178.39), respectively, in patients with ulcerative colitis. In both groups, the greatest component of direct costs was hospitalisation.

CONCLUSIONS: Costs of IBD in Serbia are lower than in more developed countries for two reasons. These include the fact that expensive biological therapy is currently under-utilised in Serbia and prices of health services are largely controlled by the State at a low level. The under-utilisation of biologicals may change with the advent of biosimilars at increasingly lower prices.

LanguageEnglish
Pages85-93
Number of pages9
JournalApplied Health Economics and Health Policy
Volume15
Issue number1
Early online date1 Sep 2016
DOIs
Publication statusPublished - 28 Feb 2017

Fingerprint

Serbia
Ulcerative Colitis
Inflammatory Bowel Diseases
Crohn Disease
Health Care Costs
Costs and Cost Analysis
Biosimilar Pharmaceuticals
Health Expenditures
Developed Countries
Biological Therapy
Cost of Illness
Costs
Health Services
Hospitalization
Economics

Keywords

  • cost of illness
  • chronic diseases
  • Servia
  • IBD
  • inflammatory bowel disease

Cite this

Kostić, Marina ; Djakovic, Ljiljan ; Šujić, Raša ; Godman, Brian ; Janković, Slobodan M. / Inflammatory bowel diseases (Crohn's disease and ulcerative colitis) : cost of treatment in Serbia and the implications. In: Applied Health Economics and Health Policy. 2017 ; Vol. 15, No. 1. pp. 85-93.
@article{66e1cb3f7bed438d929c0d1685f34316,
title = "Inflammatory bowel diseases (Crohn's disease and ulcerative colitis): cost of treatment in Serbia and the implications",
abstract = "BACKGROUND: Although the costs of treating inflammatory bowel disease (IBD) in developed countries are well established, they remain largely unknown in countries with recent histories of socio-economic transition including Serbia.OBJECTIVE: To estimate the costs of treatment including the resources used by patients with IBD in Serbia from a societal perspective. This includes both Crohn's disease and ulcerative colitis.METHODS: This cost-of-illness study was conducted to identify direct, indirect and out-of-pocket costs of treating patients with IBD in Serbia. Patients with IBD (n = 112) completed a semi-structured questionnaire with data concerning their utilisation of heath-care resources and illness-related expenditures. All costs were calculated in Republic of Serbia dinars (RSD) at a 1-year level (2014) and subsequently converted to Euros. Median values and ranges were reported to avoid potential distortions associated with mean costs.RESULTS: Median total direct costs and total indirect costs per patient per year in patients with Crohn's disease were 192,614.32RSD (€1602.97) and 28,014.00RSD (€233.13) and 142,267.15RSD (€1183.97) and 21,436.00RSD (€178.39), respectively, in patients with ulcerative colitis. In both groups, the greatest component of direct costs was hospitalisation.CONCLUSIONS: Costs of IBD in Serbia are lower than in more developed countries for two reasons. These include the fact that expensive biological therapy is currently under-utilised in Serbia and prices of health services are largely controlled by the State at a low level. The under-utilisation of biologicals may change with the advent of biosimilars at increasingly lower prices.",
keywords = "cost of illness, chronic diseases, Servia, IBD, inflammatory bowel disease",
author = "Marina Kostić and Ljiljan Djakovic and Raša Šujić and Brian Godman and Janković, {Slobodan M}",
year = "2017",
month = "2",
day = "28",
doi = "10.1007/s40258-016-0272-z",
language = "English",
volume = "15",
pages = "85--93",
journal = "Applied Health Economics and Health Policy",
issn = "1175-5652",
number = "1",

}

Inflammatory bowel diseases (Crohn's disease and ulcerative colitis) : cost of treatment in Serbia and the implications. / Kostić, Marina; Djakovic, Ljiljan; Šujić, Raša; Godman, Brian; Janković, Slobodan M.

In: Applied Health Economics and Health Policy, Vol. 15, No. 1, 28.02.2017, p. 85-93.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Inflammatory bowel diseases (Crohn's disease and ulcerative colitis)

T2 - Applied Health Economics and Health Policy

AU - Kostić, Marina

AU - Djakovic, Ljiljan

AU - Šujić, Raša

AU - Godman, Brian

AU - Janković, Slobodan M

PY - 2017/2/28

Y1 - 2017/2/28

N2 - BACKGROUND: Although the costs of treating inflammatory bowel disease (IBD) in developed countries are well established, they remain largely unknown in countries with recent histories of socio-economic transition including Serbia.OBJECTIVE: To estimate the costs of treatment including the resources used by patients with IBD in Serbia from a societal perspective. This includes both Crohn's disease and ulcerative colitis.METHODS: This cost-of-illness study was conducted to identify direct, indirect and out-of-pocket costs of treating patients with IBD in Serbia. Patients with IBD (n = 112) completed a semi-structured questionnaire with data concerning their utilisation of heath-care resources and illness-related expenditures. All costs were calculated in Republic of Serbia dinars (RSD) at a 1-year level (2014) and subsequently converted to Euros. Median values and ranges were reported to avoid potential distortions associated with mean costs.RESULTS: Median total direct costs and total indirect costs per patient per year in patients with Crohn's disease were 192,614.32RSD (€1602.97) and 28,014.00RSD (€233.13) and 142,267.15RSD (€1183.97) and 21,436.00RSD (€178.39), respectively, in patients with ulcerative colitis. In both groups, the greatest component of direct costs was hospitalisation.CONCLUSIONS: Costs of IBD in Serbia are lower than in more developed countries for two reasons. These include the fact that expensive biological therapy is currently under-utilised in Serbia and prices of health services are largely controlled by the State at a low level. The under-utilisation of biologicals may change with the advent of biosimilars at increasingly lower prices.

AB - BACKGROUND: Although the costs of treating inflammatory bowel disease (IBD) in developed countries are well established, they remain largely unknown in countries with recent histories of socio-economic transition including Serbia.OBJECTIVE: To estimate the costs of treatment including the resources used by patients with IBD in Serbia from a societal perspective. This includes both Crohn's disease and ulcerative colitis.METHODS: This cost-of-illness study was conducted to identify direct, indirect and out-of-pocket costs of treating patients with IBD in Serbia. Patients with IBD (n = 112) completed a semi-structured questionnaire with data concerning their utilisation of heath-care resources and illness-related expenditures. All costs were calculated in Republic of Serbia dinars (RSD) at a 1-year level (2014) and subsequently converted to Euros. Median values and ranges were reported to avoid potential distortions associated with mean costs.RESULTS: Median total direct costs and total indirect costs per patient per year in patients with Crohn's disease were 192,614.32RSD (€1602.97) and 28,014.00RSD (€233.13) and 142,267.15RSD (€1183.97) and 21,436.00RSD (€178.39), respectively, in patients with ulcerative colitis. In both groups, the greatest component of direct costs was hospitalisation.CONCLUSIONS: Costs of IBD in Serbia are lower than in more developed countries for two reasons. These include the fact that expensive biological therapy is currently under-utilised in Serbia and prices of health services are largely controlled by the State at a low level. The under-utilisation of biologicals may change with the advent of biosimilars at increasingly lower prices.

KW - cost of illness

KW - chronic diseases

KW - Servia

KW - IBD

KW - inflammatory bowel disease

U2 - 10.1007/s40258-016-0272-z

DO - 10.1007/s40258-016-0272-z

M3 - Article

VL - 15

SP - 85

EP - 93

JO - Applied Health Economics and Health Policy

JF - Applied Health Economics and Health Policy

SN - 1175-5652

IS - 1

ER -